|
Greetings of the day,
December issue contains some very good studies answering common questions we face every day—what is the probability of developing rheumatoid arthritis in seropositive arthralgia patients? How common is baseline LFT and RFT abnormalities in early arthritis patients and is that a contraindication to start methotrexate? Are NSAIDs safe with methotrexate in the treatment of inflammatory arthritis? Is low-dose rituximab (500 mg) effective in the treatment of rheumatoid arthritis? All this recent research is highlight of this issue. .
Two randomized clinical trials evaluating efficacy and safety of biosimilars in the treatment of AS and RA have been included in the 'Latest Research' section. This will have great economic impact.
Few prominent articles related to basic research, efficacy of oral apremilast in the treatment of AS, and important articles published from our country recently are part of this issue.
Some very useful information related to Behcet's disease has been discussed in 'Expert Opinion' section by Prof. Yusuf Yazici.
In this issue survey questions are for rheumatoid arthritis, with other regular columns.
Hope you will enjoy this issue.
Best regards
Editor |
